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Abstract
The ketogenic diet is a high-fat, low-carbohydrate regimen that forces ketone-based rather than glucose-based cellular
metabolism. Clinically, maintenance on a ketogenic diet has been proven effective in treating pediatric epilepsy and type II
diabetes, and recent basic research provides evidence that ketogenic strategies offer promise in reducing brain injury.
Cellular mechanisms hypothesized to be mobilized by ketone metabolism and underlying the success of ketogenic diet
therapy, such as reduced reactive oxygen species and increased central adenosine, suggest that the ketolytic metabolism
induced by the diet could reduce pain and inflammation. To test the effects of a ketone-based metabolism on pain and
inflammation directly, we fed juvenile and adult rats a control diet (standard rodent chow) or ketogenic diet (79% fat) ad
libitum for 3–4 weeks. We then quantified hindpaw thermal nociception as a pain measure and complete Freund’s adjuvant-
induced local hindpaw swelling and plasma extravasation (fluid movement from the vasculature) as inflammation measures.
Independent of age, maintenance on a ketogenic diet reduced the peripheral inflammatory response significantly as
measured by paw swelling and plasma extravasation. The ketogenic diet also induced significant thermal hypoalgesia
independent of age, shown by increased hindpaw withdrawal latency in the hotplate nociception test. Anti-inflammatory
and hypoalgesic diet effects were generally more robust in juveniles. The ketogenic diet elevated plasma ketones similarly
in both age groups, but caused slowed body growth only in juveniles. These data suggest that applying a ketogenic diet or
exploiting cellular mechanisms associated with ketone-based metabolism offers new therapeutic opportunities for
controlling pain and peripheral inflammation, and that such a metabolic strategy may offer significant benefits for children
and adults.
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Introduction
Pain and inflammation are hallmarks of diverse acute and
chronic diseases. Chronic pain is one of the most commonly
indicated health-related factors leading to poor quality of life [1,2],
and, across all cultures, patients with chronic pain have among the
lowest reported quality-of-life scores of any medical condition
[1,2]. In parallel, accumulating evidence points to inflammation as
not simply a consequence but an active contributor to pathologies
such as atherosclerosis, stroke, metabolic syndrome and cancer
[3]. Without question, a great unmet public health need exists for
safe, effective and non-addictive strategies to reduce pain and
inflammation.
Dietary therapy has long been coveted as a strategy to treat a
variety of clinical conditions, including pain and inflammation.
For example, polyunsaturated fatty acids reduce nociception by
activating peroxisome proliferator-activated receptors (PPARs) [4],
and olive oil polyphenolic compounds reduce experimental
inflammation [5]. In addition to specialized dietary approaches,
chronic caloric restriction reduces inflammation in several models
[6,7]. Benefits of metabolic therapy are demonstrated unequivo-
cally in disorders of amino acid metabolism (such as phenylke-
tonuria), familial hypercholesterolemia, and disorders of fatty acid
transport and oxidation [8,9]. Overall, metabolism has clear
effects on the central nervous system and a host of peripheral
tissues, and strategies that exploit broadly the therapeutic benefits
of metabolism are becoming more compelling in translational and
clinical research [10–12].
Evidence is building steadily on the effectiveness of a ketogenic
diet – a high-fat, low-carbohydrate regimen – in treating epilepsy,
brain cancer, type II diabetes and neurodegeneration [13–15]. For
decades the ketogenic diet has been used successfully to treat
epilepsy, particularly pediatric and medically refractory epilepsy,
and its efficacy has been validated by a host of multi-center,
retrospective and randomized, prospective clinical studies
[13,16,17]. The restricted carbohydrate content of a ketogenic
diet minimizes glucose metabolism and increases ketolysis, i.e., the
use of ketone bodies (acetone, acetoacetate, b-hydroxybutyrate) as
alternate energy sources. Established cellular consequences and
recently hypothesized mechanisms of ketogenic diet therapy
[18–21] coalesce to suggest that a predominantly ketone-based
metabolism may reduce inflammation and nociception as
compared to glucose-based metabolism [12].
To date, published data characterizing the relationship among
ketogenic diets, pain and inflammation are limited. A pilot clinical
study showed that a ketogenic diet reduced inflammation in non-
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alcoholic fatty liver disease [22], and a need for more research on
this topic has been noted recently [12,23]. Data characterizing
ketogenic diets and pain are also limited [24], although the use of
anticonvulsant drugs as antihyperalgesic/antiallodynic agents for
neuropathic pain suggests that an anticonvulsant ketogenic diet
might be effective in reducing pain. In the present study we
evaluated the therapeutic potential of a ketogenic diet directly by
quantifying standard measures of pain and inflammation in
juvenile and adult rats. We found that maintenance on an ad
libitum ketogenic diet for three weeks attenuates thermal
nociception and decreases a peripheral inflammatory response
significantly in both age groups. These results indicate that
metabolism-based strategies may offer new therapeutic opportu-
nities with broad clinical implications.
Results
Latency to hindpaw withdrawal from a hotplate is a standard
test for thermal nociception. All animals were tested with one
temperature per day for six days (46–51uC). As expected, all diet
and age groups exhibited a significant decrease in latency to
hindpaw withdrawal as hotplate temperature increased (Figure 1).
There was, however, notable hypoalgesia in the ketogenic diet-fed
groups. Withdrawal latencies were significantly longer at temper-
atures 48–51uC in juveniles (Figure 1, top) and 49–50uC in adults
(Figure 1, bottom). No significant differences were found at other
temperatures. The diet effect appeared to be stronger in juveniles,
with a larger rightward shift of the temperature-response curve
and more highly significant post-hoc comparisons (Figure 1).
Overall, maintenance on a ketogenic diet produced a clear
hypoalgesic effect in juvenile and adult rats as assessed by hot plate
testing.
We quantified peripheral inflammation in response to local
injection of complete Freund’s adjuvant (CFA). Just prior to CFA
injection, hindpaw volumes of juvenile and adult rats maintained
on a ketogenic versus control diet for 3 wk were measured. As
expected, there was no significant right/left asymmetry in baseline
hindpaw volume in any group and thus baseline right/left ratios
were not different than 1.0 (Figure 2). Each animal received a CFA
injection into the right hindpaw and we measured right/left
hindpaw volume 48 h after CFA injection (peripheral inflamma-
tion peaks at approximately 48 h). The right/left ratio significant
increased in all age and diet groups, indicating right hindpaw paw
swelling. However, the ratio (and thus the injected paw volume)
was significantly lower in both age groups fed the ketogenic diet
(Figure 2). The swelling induced by CFA injection was similar in
both age groups on the control diet, and the significant anti-
inflammatory effect of the ketogenic diet was also similar in both
age groups (Figure 2).
To further characterize the peripheral inflammatory response,
we quantified plasma extravasation, a measure of the movement of
fluid to the extravascular space. Consistent with the reduced
hindpaw swelling, ketogenic diet-fed rats of both ages had a
significantly attenuated plasma extravasation response to CFA as
compared to control diet-fed rats (Figure 3). The magnitude of the
effect appeared to be larger in juveniles (extravasation attenuated
by 5067%) than in adults (attenuated by 3168%).
Even with ad libitum feeding, ketogenic diet-fed juveniles had
significantly slower weight gain and growth rate as compared to
juveniles on a control diet (Figure 4A), similar to clinical findings in
pediatric epilepsy [25]; nevertheless, ketogenic diet-fed juveniles
appeared healthy and active. Consistent with their lower body
weight, ketogenic diet-fed juveniles had a significantly lower
baseline hindpaw volume (Figure 4B) and so were injected with a
Figure 1. Hindpaw thermal nociception is decreased in juvenile
and adult rats fed the ketogenic diet. Top: juvenile; Bottom: adult.
All animals were tested on one temperature per day. Increasing hot
plate temperature led to reduced withdrawal latency in all groups, and
temperature-response curves were similar for juveniles and adults on
the control diet (control diet – filled symbols, ketogenic diet – empty
symbols). The ketogenic diet increased latencies in both age groups,
with a more robust effect in juveniles. Analysis of juveniles revealed
significant effects of temperature (F = 100.7, p,0.001) and diet (F = 18.9,
p,0.001), and a significant diet x temperature interaction (F = 7.1,
p,0.001). Analysis of adults revealed significant effects of temperature
(F = 101.0, p,0.001) and diet (F = 4.8, p,0.05), and a significant diet x
temperature interaction (F = 2.7, p,0.05). Numbers of subjects: 12 for
each juvenile group, 14 for adult control diet, 16 for adult ketogenic
diet. *p,0.05, **p,0.01, ***p,0.001; Newman-Keuls comparison to
temperature-matched controls.
doi:10.1371/journal.pone.0008349.g001
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proportional volume of CFA into the paw. In adults, there was no
significant effect on weight (and no difference in hindpaw volume)
between animals fed a ketogenic diet versus control diet (Figure 4A,
B). Thus, hindpaw CFA injection volume was the same in all
adults. The ketogenic diet increased blood ketones strongly and
equivalently in juveniles and adults (Figure 4C). Therefore,
differences in the level of ketosis do not account for the greater
effects of the ketogenic diet in juvenile rats on some of the present
measures.
Discussion
Here we demonstrate hypoalgesic and anti-inflammatory effects
of a ketogenic diet. In juvenile and adult rats we show that ad
libitum feeding of a ketogenic diet reduces nociception, as assessed
by hindpaw withdrawal latency, and peripheral inflammation, as
assessed by CFA-induced hindpaw swelling and plasma extrava-
sation. To date the clinical applications of ketogenic strategies
have focused primarily on its established success with pediatric
epilepsy [13] and emerging success with diabetes [26]; recent
translational research is expanding clinical implications to include
brain cancer, brain injury, and Rett syndrome [14,15,27]. New
therapies are particularly urgent for pain, inflammation and
inflammatory pain, and the present data suggest more transla-
tional research is needed for ketogenic diet therapy and analogous
metabolic treatments.
There are a number of mechanisms thought to underlie the
efficacy of ketogenic diet therapy, but an incomplete understand-
ing of critical cellular mechanisms has hampered efforts to develop
alternate pharmacological strategies and, in parallel, limited
clinical predictions and applications of this type of metabolic
therapy. However, published experimental research and hypoth-
eses regarding the success of ketogenic diet therapy point to its
clinical potential for pain and inflammation [18–21]. With respect
to central pain mechanisms and neuronal activity, ketolytic
metabolism is thought to increase levels of adenosine and/or
GABA, two powerful inhibitory substances in the nervous system,
through augmented oxidative phosphorylation and shifted gluta-
mate:aspartate aminotransferase equilibrium, respectively [18,28].
There is abundant evidence that increasing central inhibition by
activating adenosine A1, GABAA or GABAB receptors produces
hypoalgesia in acute pain tests [29,30]. In addition to central
mechanisms, a high polyunsaturated fatty acid content in
ketogenic diets should enhance potassium conductances in
peripheral neurons through PPAR activation [4,31]. Therefore,
we speculate that mechanistically-separate inhibitory processes in
the central and peripheral nervous system could combine to
mediate ketogenic diet-induced thermal hypoalgesia. Given the
positive effects of adenosine and GABA agonists in treating
chronic inflammatory and neuropathic pain [30,32,33] and the
central hyperexcitability in chronic pain [34], ketogenic diets
might be especially effective analgesics/hypoalgesics for diverse
types of chronic pain. The success of dietary therapy even in
pharmacoresistant epilepsy suggests that it may also be effective for
intractable pain.
In addition to decreased nociception, we show that pretreat-
ment with a ketogenic diet reduces subcutaneous inflammation
significantly in juvenile and adult animals. There are multiple
possible mechanisms. Ketone metabolism results in a decreased
production of reactive oxygen species [35,36], known to contribute
to inflammation [37]. Adenosine acting through A1 and A2
receptor subtypes limits inflammation in a wide variety of
peripheral and central tissues [38,39], including inflammation
due to subcutaneous inflammogens [30,40]. Polyunsaturated fatty
acid-induced PPAR activation inhibits NFkB and AP-1, both pro-
inflammatory transcription factors [20]. It is possible that each is
involved, and more research is needed to elucidate the primary
Figure 2. Hindpaw inflammatory swelling is reduced in juveniles
and adults fed the ketogenic diet. Control diet – filled symbols,
ketogenic diet – empty symbols for juveniles (left) and adults (right).
Hindpaw volumes are shown as right/left ratios, measured just prior to
and 48 h after injection of CFA into the right hindpaw. As expected,
baseline ratios are similar to 1.0 in all groups. CFA-induced swelling was
similar in juvenile and adult rats (71% and 72%, respectively), and was
attenuated significantly by the ketogenic diet in both age groups. Analysis
of juveniles indicated a significant effect of CFA (F=68.7, p,0.001), and a
significant diet x CFA interaction (F= 5.4, p,0.05). Analysis of adults
indicated significant effects of CFA (F=183.6, p,0.001) and a significant
diet x CFA interaction (F= 7.5, p,0.05). Numbers of subjects: 7 for juvenile
control diet, 6 for juvenile ketogenic diet, 12 for adult control diet, 11 for
adult ketogenic diet. * p,0.05, *** p,0.001 Newman-Keuls comparisons
to post-CFA controls.
doi:10.1371/journal.pone.0008349.g002
Figure 3. CFA-induced plasma extravasation is reduced in
juvenile and adult rats fed the ketogenic diet. Control diet – solid
bar, ketogenic diet – open bar for juveniles (left) and adults (right).
Values are shown as right/left ratios and so would be near 1.0 for
untreated animals. CFA-induced plasma extravasation was attenuated
significantly by a ketogenic diet in juvenile and adult rats; CFA-induced
plasma extravasation was lower overall in juveniles. *p,0.05, t-test
comparisons to age-matched controls. Number of subjects: 5 for
juvenile control diet, 6 for juvenile ketogenic diet, 10 for adult control
diet, 11 for adult ketogenic diet.
doi:10.1371/journal.pone.0008349.g003
Ketosis, Pain and Inflammation
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mechanism underlying this peripheral effect. In addition to specific
cellular mechanisms, overall protein restriction reduces inflamma-
tion in some situations [41,42], and caloric restriction is anti-
inflammatory in general [6,7]. All animals in this study were fed ad
libitum, thus it is unlikely that caloric restriction is occurring in the
present study in the adult animals, a group that showed no
difference in weight but did exhibit significantly reduced
inflammation (and nociception) on the ketogenic diet. Neverthe-
less, a combined calorically-restrictive and ketogenic diet may be
even more effective against inflammation (and potentially
nociception) than either dietary component alone; similar
conclusions have been made concerning the anticonvulsive and
anticancer effects of dietary treatments [14,43]. Furthermore,
although we used the ketogenic diet as a pretreatment, clinical
evidence suggests that it can reduce pre-existing liver inflammation
[22].
In the one published study of nociception and the ketogenic diet,
Ziegler et al. [24] described decreased (rather than increased) tail-
flick latency in rats fed a ketogenic diet. Though both the hotplate
and tail-flick involve thermal nociception, this difference may be
related to methodological differences including rat strain, body part
tested, diet composition, stimulus strength (latencies are generally
longer in our study), and length of dietary treatment (12 wk in
Ziegler et al.). The length of treatment might be particularly
important, as a number of studies using several different measures
have demonstrated non-monotonic effects of ketogenic diets at time
scales of days to weeks [44,45]. These variables should be examined
in future studies, along with other pain modalities.
Complementing our direct experimental evidence, multiple
hypotheses regarding the mechanisms underlying the success of
ketogenic diet therapy coalesce to suggest that this metabolic
treatment will reduce pain and inflammation. Yet despite
widespread interest in dietary therapies for pain and inflammation
(and myriad diseases that implicate inflammation as either a cause
or a consequence of the pathology) systematic study of ketogenic
strategies as anti-inflammatory or hypoalgesic strategies is just
beginning. Unlike myriad dietary regimens with limited or
inconsistent proof-of-efficacy, a ketogenic diet offers recognized
and established clinical benefits [13]. Accordingly, there is a focus
on elucidating critical mechanisms underlying the success of
ketogenic diet therapy in treating epilepsy as well as mechanisms
underlying emerging benefits in clinical conditions such as
diabetes, brain injury, brain cancer and Rett syndrome
[12,14,26,46,47]. The data presented herein suggest that ketogenic
diets offer promising therapeutic potential for diverse inflamma-
tory or painful conditions, across age groups, without the added
difficulty of maintaining caloric restriction. Based on these results
and many decades of clinical experience with diet-based therapies
for pediatric epilepsy, a novel anti-inflammatory and hypoalgesic
application of ketogenic diet therapy (or an analogous future
pharmacological strategy) would be effective, non-addictive and
relatively free of major side effects.
Materials and Methods
Male Sprague-Dawley rats were bred in the Trinity College
vivarium with animals originally purchased from Charles River
(Storrs Mansfield, Connecticut, USA). All experiments were
carried out in accordance with the NIH Guide for the Care and
Use of Laboratory Animals and with approval of the Trinity
College animal care and use committee. Either shortly after
weaning at 21 d or as adults (85–110 d), matched groups of male
Sprague-Dawley rats were switched to a ketogenic diet (AIN-76
Modified, High fat, #3666; Bio-Serv, Frenchtown, New Jersey,
USA) or maintained on their standard diet (Purina 5001;
PharmaServ, Framingham, Massachusetts, USA). Sprague-Daw-
ley rats become ketotic within 5 d of ad libitum feeding of this
particular ketogenic diet [48]. All animals were weighed twice
weekly until the start of testing. All animals appeared healthy and
normally active during dietary treatment.
After 3 weeks, and during continuing dietary treatment, rats
were tested on a hotplate (Columbus Instruments, Columbus,
Figure 4. The ketogenic diet retards growth in juvenile but not adult rats, while inducing equivalent ketosis. A: All groups gained
weight over three weeks. There was no difference in weight gain between diet groups in the adult animals; juvenile animals on the ketogenic diet
gained weight significantly more slowly than those on the control diet. Analysis of juveniles revealed significant effects of time (F = 635.1, p,0.001)
and diet (F = 17.6, p,0.001), as well as a significant time x diet interaction (F = 241.8, p,0.001), whereas for adults, there was a significant effect of
time (F = 62.7, p,0.001) but not diet (F = 1.2, n.s.) and no significant interaction (F = 1.2, n.s.). Numbers of subjects: 12 for each juvenile group, 14 for
adult control diet, 16 for adult ketogenic diet. B: Like body weight, baseline paw size (before CFA injection) was lower with the ketogenic diet in
juveniles but not in adults. Numbers of subjects as in Fig. 2. C: Plasma levels of the ketone body b-hydroxybutyrate were similarly elevated in juvenile
and adult rats. Analysis revealed a significant effect of diet (F = 49.6, p,0.001) but not age (F = 0.8, n.s.) and no significant interaction (F = 0.8, n.s.).
Number of subjects = 7–9. *p,0.05, **p,0.01, ***p,0.001 Newman-Keuls (A,C) or t-test (B) comparisons to age-matched controls.
doi:10.1371/journal.pone.0008349.g004
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Ohio, USA) at each integer temperature between and including
46u and 51uC; one temperature was tested per day, in ascending
order. Based on preliminary testing, this temperature range started
at a temperature that rarely produced a nocifensive response
within 60 s (46uC) and went up in integers to the temperature that
produced a response by approximately 10 s in control diet animals
(51uC). To quantify thermal nociception at each temperature, rats
were placed on the hot plate and the latency recorded to hindpaw-
associated nocifensive behavior, typically suspension of the
hindpaw or hindpaw-directed licking. Once such signs were
observed, animals were removed immediately. To prevent any
tissue damage, rats that reached 60 s without a response were
removed and scored as 60 s.
After 4 weeks of dietary treatment, rats received an intraplantar
injection of CFA (a suspension of heat-killed Mycobacterium
tuberculosis, undiluted) in the right hindpaw to induce a consistent
and sustained local inflammation. Hindpaw sizes were measured
by volume displacement and paralleled total body size (Figure 4,
right); the amount of injected CFA was adjusted accordingly to
give an equivalent dose per paw size. CFA injection volume
ranged from 100 ml (juveniles on ketogenic diet) to 190 ml (adults).
Hindpaw size was measured by volume displacement just before
and at 48 h after injection, a time-point selected to approximate
the maximal inflammatory response; diet treatments were
continued during this 48 h interval.
After final volume measurements, the dye Evans Blue was
injected intravenously (60 mg/kg in a tail vein) to assess plasma
extravasation (fluid movement from the intra- to the extravascular
space), a major component of the inflammatory response. Tail
vein injections were unsuccessful in four rats, and these were
excluded from analysis. Two h after injection, rats were sacrificed
by anesthesia overdose. After allowing intravascular dye to drain,
hindpaw tissue was soaked in formamide at room temperature for
several days to leach out extravascular dye. Duplicate aliquots of
formamide were measured for optical density at 630 nm to
quantify the level of Evans Blue. For juveniles, the same rats were
used for pain and inflammation studies (baseline paw measure-
ments and CFA injections occurred 1 d after the last hot plate
test); for adults, separate groups were used. In all cases, CFA
injection occurred after approximately four weeks of dietary
treatment.
In a separate cohort of animals, trunk blood was collected after
3.5–4 wk of dietary treatment to assess levels of circulating
ketones. These animals were not injected with CFA or Evans blue.
Plasma b-hydroxybutyrate was measured with a Precision Xtra
monitor and ketone test strips (Abbott Laboratories; Abbott Park,
Illinois, USA).
Chemicals and CFA were purchased from Sigma-Aldrich (St.
Louis, Missouri, USA). Data were analyzed with unpaired t-test or
two-way repeated-measures analysis of variance as appropriate.
Data are presented as mean6standard error.
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